바이오에프디엔씨

251120KOSDAQ

67.8 / 100

Reference Date: 2026-09-08

Financial Score30.5 / 40

News Sentiment21.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Slightly up 5.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

BioFDC specializes in developing and manufacturing effective substances for cosmetics, health foods, and pharmaceuticals using plant cell platform technology, leveraging gene editing and high-frequency processing techniques for a unique cultivation platform. Key products include plant cell extracts and growth factor-based cosmetic ingredients, with plans to commercialize pharmaceuticals in the medium to long term.

Number of Employees

78people

Average Salary

55.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

11.05Industry Average 15.006.5Point

Lower than industry avg (good)

PBR

1.08Industry Average 1.204.0Point

In line with industry avg

ROE

10.03Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

0.35Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.2% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲12.6% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 9.1% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
바이오에프디엔씨, PDRN 소재 10종 유럽 코스모스 인증 취득
바이오에프디엔씨의 식물세포 유래 PDRN 소재가 유럽 코스모스 인증을 획득하여 국제 시장 진출에 긍정적 영향을 미칠 것으로 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 8,640Won52-week high 19,35052-week low 7,090

1-month return4.0Point

1m +4.98% (slight rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral기업설명회(IR)개최2026-09-07
Neutral반기보고서 (2026.06)2026-08-14